March 5 (Reuters) - A weekly injection of semaglutide
was safe and reduced the amount of fat in the liver by 31% in
people with HIV and a type of liver disease, a study funded by
the National Institutes of Health showed on Tuesday.
Semaglutide is sold as popular diabetes and weightloss drug
Ozempic and Wegovy by Novo Nordisk.